Has Leonard Doberne received payments from drug or device companies?

Yes. Drug and device makers reported $2,564 in general payments to Leonard Doberne across 121 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leonard Doberne did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leonard Doberne come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leonard Doberne

Endocrinology, Diabetes & Metabolism · Mountain View, CANPI 1558447847

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,319 and has fallen 74.2% since, to $340 in 2022.

$2,564in general payments, 2019–2025

Across 121 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$425
Novo Nordisk$303
Corcept Therapeutics$261
Amgen$250
Sanofi-aventis U.S. LLC$231
Boehringer Ingelheim$189
plus $904 from 12 others

What the payments were for

Food & beverage$2,50998%
Education$552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	21	$425
Novo Nordisk	17	$303
Corcept Therapeutics	7	$261
Amgen(2 entities)	12	$250
Sanofi-aventis U.S. LLC	13	$231
Boehringer Ingelheim	9	$189
Radius Health, Inc.	6	$139
AbbVie	7	$125
AstraZeneca(2 entities)	7	$122
Zealand Pharma US, Inc.	3	$100
BD	3	$96
Abbott	4	$81
Insulet Corporation	3	$58
Lifescan, Inc.	3	$52
Shire North American Group Inc	2	$49
Mannkind Corporation	2	$37
IBSA Pharma Inc.	1	$28
Xeris Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Korlym$109

How this compares

$2,564 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Other endocrinology, diabetes & metabolism in Mountain View

Todd KayeMountain View$298K
Juan FriasSan Diego$1.4M
Joselito CabaccanSan Jose$1.4M
Daniel NadeauNewport Beach$1.2M
Yehuda HandelsmanTarzana$1M
Helen BaronRancho Mirage$958K
Ken FujiokaSan Diego$747K
Minou TranPico Rivera$663K
James ChuMonterey$639K
Anthony HeaneyLos Angeles$588K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →